MEA Brain Cancer Diagnostic Market - Industry Trends and Forecast to 2030

Description

List of Tables

Middle East & Africa brain cancer diagnostic market is projected to register a substantial CAGR of 16.9 % in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation

Middle East & Africa Brain Cancer Diagnostic Market, By Test Type (Imaging Test, Biopsy, Lumber Puncture, Molecular Testing, Electroencephalography (EEG), and Others), Cancer Type (Acoustic Neuroma, Astrocytomas, Glioblastoma Multiforme, Meningiomas, Oligodendroglioma, and Others), Age Group (Below 21,21-34, 35-65, and 65 and Above), End User (Hospitals, Specialty Clinics, Diagnostic Centers & Research Institutes, Ambulatory Surgical Centers, and Others), Country (South Africa, Saudi Arabia, UAE, Egypt, Kuwait, and the rest of the Middle East and Africa), Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Middle East & Africa brain cancer diagnostic market are:

Rising cases of brain cancer worldwide

Rising awareness of early diagnosis of brain cancer

Improved imaging techniques

Innovations in drug delivery to brain cancer cells

Market Players

Some of the key market players for the Middle East & Africa brain cancer diagnostic market are listed below:

NIHON KOHDEN CORPORATION.

FUJIFILM Holdings Corporation

GE HealthCare

Koninklijke Philips N.V.

Siemens Healthcare GmbH

Canon Inc.

Others

1 INTRODUCTION 24

1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET 24
1.4 CURRENCY AND PRICING 26
1.5 LIMITATIONS 26
1.6 MARKETS COVERED 26

2 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION 29

2.1 MARKETS COVERED 29
2.2 GEOGRAPHICAL SCOPE 30
2.3 YEARS CONSIDERED FOR THE STUDY 31
2.4 DBMR TRIPOD DATA VALIDATION MODEL 32
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 35
2.6 MULTIVARIATE MODELLING 36
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 36
2.8 DBMR MARKET POSITION GRID 37
2.9 VENDOR SHARE ANALYSIS 39
2.10 MARKET END USER COVERAGE GRID 40
2.11 SECONDARY SOURCES 41

3 EXECUTIVE SUMMARY 42

4 PREMIUM INSIGHTS 44

4.1 PESTEL ANALYSIS 45
4.2 PORTER'S FIVE FORCES 46

5 EPIDEMIOLOGY 47

6 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, INDUSTRY INSIGHT 48

7 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, REGULATIONS 49

7.1 REGULATORY SCENARIO IN THE U.S 49
7.2 REGULATORY SCENARIO IN AUSTRALIA 50
7.3 REGULATORY SCENARIO IN JAPAN 50
7.4 REGULATORY SCENARIO IN CHINA 50

8 MARKET OVERVIEW 52

8.1 DRIVERS 54
- 8.1.1 RISING CASES OF BRAIN CANCER WORLDWIDE 54
- 8.1.2 RISING AWARENESS OF THE EARLY DIAGNOSIS OF BRAIN CANCER 54
- 8.1.3 IMPROVED IMAGING TECHNIQUES 55
- 8.1.4 INNOVATIONS IN DRUG DELIVERY TO BRAIN CANCER CELLS 55
8.2 RESTRAINTS 56
- 8.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS & TREATMENT FOR BRAIN CANCER 56
- 8.2.2 SIDE EFFECTS OF BRAIN CANCER TREATMENT DRUGS & THERAPIES 56
- 8.2.3 LATE DIAGNOSIS OF BRAIN CANCER RESULTING IN POOR PROGNOSIS 57
8.3 OPPORTUNITIES 57
- 8.3.1 INCREASING INVESTMENT AND FUNDING BY EMERGING PLAYERS 57
- 8.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTIC 57
- 8.3.3 RISING HEALTHCARE EXPENDITURE 58
8.4 CHALLENGES 59
- 8.4.1 STRINGENT REGULATORY REQUIREMENTS FOR DIAGNOSTIC PRODUCTS 59
- 8.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS 59

9 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE 60

9.1 OVERVIEW 61
9.2 IMAGING TEST 64
- 9.2.1 CT SCAN 65
- 9.2.2 MRI 65
- 9.2.3 PET 65
- 9.2.4 OTHERS 65
9.3 MOLECULAR TESTING 66
9.4 ELECTROENCEPHALOGRAPHY (EEG) 66
9.5 LUMBAR PUNCTURE 67
9.6 BIOPSY 68
- 9.6.1 OPEN BIOPSY 69
- 9.6.2 STEREOTACTIC BIOPSY 69
- 9.6.3 NEEDLE BIOPSY 69
- 9.6.4 NEUROENDOSCOPY 69
9.7 OTHERS 69

10 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE 70

10.1 OVERVIEW 71
10.2 GLIOBLASTOMA MULTIFORME 74
10.3 MENINGIOMAS 75
10.4 ASTROCYTOMAS 76
10.5 ACOUSTIC NEUROMA 77
10.6 OLIGODENDROGLIOMA 78
10.7 OLIGODENDROGLIOMA 78
10.8 OTHERS 79

11 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP 80

11.1 OVERVIEW 81
11.2 35-65 84
11.3 65 AND ABOVE 85
11.4 BELOW 21 86
11.5 21-34 87

12 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER 88

12.1 OVERVIEW 89
12.2 HOSPITALS 92
12.3 SPECIALTY CLINICS 93
12.4 DIAGNOSTIC CENTERS & RESEARCH INSTITUTES 94
12.5 AMBULATORY SURGICAL CENTERS 95
12.6 OTHERS 96

13 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY REGION 97

13.1 MIDDLE EAST AND AFRICA 98
- 13.1.1 SOUTH AFRICA 105
- 13.1.2 SAUDI ARABIA 107
- 13.1.3 U.A.E. 109
- 13.1.4 KUWAIT 111
- 13.1.5 EGYPT 113
- 13.1.6 REST OF MIDDLE EAST AND AFRICA 115

14 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY LANDSCAPE 116

14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 116

15 SWOT ANALYSIS 117

16 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, COMPANY PROFILE 118

16.1 KONINKLIJKE PHILIPS N.V. 118
- 16.1.1 COMPANY SNAPSHOT 118
- 16.1.2 REVENUE ANALYSIS 118
- 16.1.3 COMPANY SHARE ANALYSIS 119
- 16.1.4 PRODUCT PORTFOLIO 119
- 16.1.5 RECENT DEVELOPMENTS 120
16.2 CANON INC. 121
- 16.2.1 COMPANY SNAPSHOT 121
- 16.2.2 REVENUE ANALYSIS 121
- 16.2.3 COMPANY SHARE ANALYSIS 122
- 16.2.4 PRODUCT PORTFOLIO 122
- 16.2.5 RECENT DEVELOPMENT 122
16.3 SIEMENS HEALTHCARE GMBH 123
- 16.3.1 COMPANY SNAPSHOT 123
- 16.3.2 REVENUE ANALYSIS 124
- 16.3.3 COMPANY SHARE ANALYSIS 124
- 16.3.4 PRODUCT PORTFOLIO 125
- 16.3.5 RECENT DEVELOPMENTS 125
16.4 BD 126
- 16.4.1 COMPANY SNAPSHOT 126
- 16.4.2 REVENUE ANALYSIS 127
- 16.4.3 COMPANY SHARE ANALYSIS 127
- 16.4.4 PRODUCT PORTFOLIO 128
- 16.4.5 RECENT DEVELOPMENTS 128
16.5 NIHON KOHDEN CORPORATION. 129
- 16.5.1 COMPANY SNAPSHOT 129
- 16.5.2 RECENT FINANCIALS 129
- 16.5.3 COMPANY SHARE ANALYSIS 130
- 16.5.4 PRODUCT PORTFOLIO 130
- 16.5.5 RECENT DEVELOPMENT 130
16.6 BIOCEPT, INC. 131
- 16.6.1 COMPANY SNAPSHOT 131
- 16.6.2 REVENUE ANALYSIS 131
- 16.6.3 PRODUCT PORTFOLIO 132
- 16.6.4 RECENT DEVELOPMENT 132
16.7 BIOMIND 133
- 16.7.1 COMPANY SNAPSHOT 133
- 16.7.2 PRODUCT PORTFOLIO 133
- 16.7.3 RECENT DEVELOPMENT 133
16.8 CEREBRAL DIAGNOSTIC 134
- 16.8.1 COMPANY SNAPSHOT 134
- 16.8.2 PRODUCT PORTFOLIO 134
- 16.8.3 RECENT DEVELOPMENT 134
16.9 DXCOVER LIMITED 135
- 16.9.1 COMPANY SNAPSHOT 135
- 16.9.2 PRODUCT PORTFOLIO 135
- 16.9.3 RECENT DEVELOPMENT 135
16.10 FONAR CORP. 136
- 16.10.1 COMPANY SNAPSHOT 136
- 16.10.2 REVENUE ANALYSIS 136
- 16.10.3 PRODUCT PORTFOLIO 137
- 16.10.4 RECENT DEVELOPMENT 137
16.11 FUJIFILM CORPORATION 138
- 16.11.1 COMPANY SNAPSHOT 138
- 16.11.2 REVENUE ANALYSIS 138
- 16.11.3 PRODUCT PORTFOLIO 139
- 16.11.4 RECENT DEVELOPMENT 139
16.12 GE HEALTHCARE. 140
- 16.12.1 COMPANY SNAPSHOT 140
- 16.12.2 REVENUE ANALYSIS 140
- 16.12.3 PRODUCT PORTFOLIO 141
- 16.12.4 RECENT DEVELOPMENT 141
16.13 HITACHI, LTD. 142
- 16.13.1 COMPANY SNAPSHOT 142
- 16.13.2 REVENUE ANALYSIS 142
- 16.13.3 PRODUCT PORTFOLIO 143
- 16.13.4 RECENT DEVELOPMENT 143
16.14 MINFOUND MEDICAL SYSTEMS CO., 144
- 16.14.1 COMPANY SNAPSHOT 144
- 16.14.2 PRODUCT PORTFOLIO 144
- 16.14.3 RECENT DEVELOPMENT 144
16.15 NANTOMICS. 145
- 16.15.1 COMPANY SNAPSHOT 145
- 16.15.2 PRODUCT PORTFOLIO 145
- 16.15.3 RECENT DEVELOPMENT 145
16.16 NEUSOFT CORPORATION 146
- 16.16.1 COMPANY SNAPSHOT 146
- 16.16.2 REVENUE ANALYSIS 146
- 16.16.3 PRODUCT PORTFOLIO 147
- 16.16.4 RECENT DEVELOPMENT 147
16.17 SEQUOIA HEALTHCARE. 148
- 16.17.1 COMPANY SNAPSHOT 148
- 16.17.2 PRODUCT PORTFOLIO 148
- 16.17.3 RECENT DEVELOPMENT 148
16.18 STERNMED GMBH 149
- 16.18.1 COMPANY SNAPSHOT 149
- 16.18.2 PRODUCT PORTFOLIO 149
- 16.18.3 RECENT DEVELOPMENT 149
16.19 THERMO FISHER SCIENTIFIC INC. 150
- 16.19.1 COMPANY SNAPSHOT 150
- 16.19.2 REVENUE ANALYSIS 150
- 16.19.3 PRODUCT PORTFOLIO 151
- 16.19.4 RECENT DEVELOPMENT 151
16.20 TIME MEDICAL HOLDING. 152
- 16.20.1 COMPANY SNAPSHOT 152
- 16.20.2 PRODUCT PORTFOLIO 152
- 16.20.3 RECENT DEVELOPMENTS 152

17 QUESTIONNAIRE 153

18 RELATED REPORTS 156

LIST OF TABLES

TABLE 1 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 55
TABLE 2 MIDDLE EAST & AFRICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 56
TABLE 3 MIDDLE EAST & AFRICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 57
TABLE 4 MIDDLE EAST & AFRICA MOLECULAR TESTING IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 58
TABLE 5 MIDDLE EAST & AFRICA ELECTROENCEPHALOGRAPHY (EEG) IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 59
TABLE 6 MIDDLE EAST & AFRICA LUMBAR PUNCTURE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 59
TABLE 7 MIDDLE EAST & AFRICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 60
TABLE 8 MIDDLE EAST & AFRICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 60
TABLE 9 MIDDLE EAST & AFRICA OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 61
TABLE 10 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 65
TABLE 11 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 66
TABLE 12 MIDDLE EAST & AFRICA MENINGIOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 67
TABLE 13 MIDDLE EAST & AFRICA ASTROCYTOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 68
TABLE 14 MIDDLE EAST & AFRICA ACOUSTIC NEUROMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 69
TABLE 15 MIDDLE EAST & AFRICA OLIGODENDROGLIOMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 70
TABLE 16 MIDDLE EAST & AFRICA OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 71
TABLE 17 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 75
TABLE 18 MIDDLE EAST & AFRICA 35-65 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 76
TABLE 19 MIDDLE EAST & AFRICA 65 AND ABOVE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 77
TABLE 20 MIDDLE EAST & AFRICA BELOW 21 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 78
TABLE 21 MIDDLE EAST & AFRICA 21-34 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 79
TABLE 22 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 83
TABLE 23 MIDDLE EAST & AFRICA HOSPITALS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 84
TABLE 24 MIDDLE EAST & AFRICA SPECIALTY CLINICS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 85
TABLE 25 MIDDLE EAST & AFRICA DIAGNOSTIC CENTERS & RESEARCH INSTITUTES IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 86
TABLE 26 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 87
TABLE 27 MIDDLE EAST & AFRICA OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 88
TABLE 28 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 94
TABLE 29 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 94
TABLE 30 MIDDLE EAST AND AFRICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 94
TABLE 31 MIDDLE EAST AND AFRICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 95
TABLE 32 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 95
TABLE 33 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 95
TABLE 34 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 96
TABLE 35 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 97
TABLE 36 SOUTH AFRICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 97
TABLE 37 SOUTH AFRICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 97
TABLE 38 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 98
TABLE 39 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 98
TABLE 40 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 98
TABLE 41 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 99
TABLE 42 SAUDI ARABIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 99
TABLE 43 SAUDI ARABIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 99
TABLE 44 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 100
TABLE 45 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 100
TABLE 46 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 100
TABLE 47 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 101
TABLE 48 U.A.E. IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 101
TABLE 49 U.A.E. BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 101
TABLE 50 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 102
TABLE 51 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 102
TABLE 52 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 102
TABLE 53 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 103
TABLE 54 KUWAIT IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 103
TABLE 55 KUWAIT BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 103
TABLE 56 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 104
TABLE 57 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 104
TABLE 58 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 104
TABLE 59 EGYPT BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 105
TABLE 60 EGYPT IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 105
TABLE 61 EGYPT BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 105
TABLE 62 EGYPT BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 106
TABLE 63 EGYPT BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 106
TABLE 64 EGYPT BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 106
TABLE 65 REST OF MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 107

LIST OF FIGURES

FIGURE 1 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION 20
FIGURE 2 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION 23
FIGURE 3 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: DROC ANALYSIS 24
FIGURE 4 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS 25
FIGURE 5 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 25
FIGURE 6 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS 26
FIGURE 7 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: DBMR POSITION GRID 28
FIGURE 8 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS 30
FIGURE 9 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: END USER COVERAGE GRID 31
FIGURE 10 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION 34
FIGURE 11 RISING CASES OF BRAIN CANCER WORLDWIDE & IMPROVED IMAGING TECHNIQUES ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030 35
FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030 35
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET 44
FIGURE 14 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, 2022 52
FIGURE 15 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE 2023-2030 (USD MILLION) 53
FIGURE 16 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030) 53
FIGURE 17 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE 54
FIGURE 18 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, 2022 62
FIGURE 19 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE 2023-2030 (USD MILLION) 63
FIGURE 20 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, CAGR (2023-2030) 63
FIGURE 21 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, LIFELINE CURVE 64
FIGURE 22 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2022 72
FIGURE 23 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2023-2030 (USD MILLION) 73
FIGURE 24 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, CAGR (2023-2030) 73
FIGURE 25 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, LIFELINE CURVE 74
FIGURE 26 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2022 80
FIGURE 27 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION) 81
FIGURE 28 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030) 81
FIGURE 29 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE 82
FIGURE 30 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022) 90
FIGURE 31 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022) 91
FIGURE 32 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030) 91
FIGURE 33 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030) 92
FIGURE 34 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030) 92
FIGURE 35 MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%) 107